학술논문

Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson's disease.
Document Type
Article
Source
Brain: A Journal of Neurology. Jul2023, Vol. 146 Issue 7, p2753-2765. 13p.
Subject
*MITOCHONDRIAL DNA
*PARKINSON'S disease
*GENE expression
*MELAS syndrome
*LEBER'S hereditary optic atrophy
Language
ISSN
0006-8950
Abstract
Biallelic mutations in PINK1 / PRKN cause recessive Parkinson's disease. Given the established role of PINK1/Parkin in regulating mitochondrial dynamics, we explored mitochondrial DNA integrity and inflammation as disease modifiers in carriers of mutations in these genes. Mitochondrial DNA integrity was investigated in a large collection of biallelic (n = 84) and monoallelic (n = 170) carriers of PINK1 / PRKN mutations, idiopathic Parkinson's disease patients (n = 67) and controls (n = 90). In addition, we studied global gene expression and serum cytokine levels in a subset. Affected and unaffected PINK1 / PRKN monoallelic mutation carriers can be distinguished by heteroplasmic mitochondrial DNA variant load (area under the curve = 0.83, CI 0.74–0.93). Biallelic PINK1 / PRKN mutation carriers harbour more heteroplasmic mitochondrial DNA variants in blood (P = 0.0006, Z = 3.63) compared to monoallelic mutation carriers. This enrichment was confirmed in induced pluripotent stem cell-derived (controls, n = 3; biallelic PRKN mutation carriers, n = 4) and post-mortem (control, n = 1; biallelic PRKN mutation carrier, n = 1) midbrain neurons. Last, the heteroplasmic mitochondrial DNA variant load correlated with IL6 levels in PINK1 / PRKN mutation carriers (r = 0.57, P = 0.0074). PINK1 / PRKN mutations predispose individuals to mitochondrial DNA variant accumulation in a dose- and disease-dependent manner. [ABSTRACT FROM AUTHOR]